Abstract

Angiotensin II (AngII) causes hypertension (HTN) and promotes renal injury while simultaneously inducing reno-protective enzymes like heme oxygenase-1 (HO-1). We examined the modulatory role of HO on sub-pressor angiotensin II (SP-AngII) induced renal inflammation and injury. We first tested whether the SP-AngII-induced renal dysfunction, inflammation and injury are exacerbated by either preventing (chronic HO-1 inhibition) or reversing (late HO-1 inhibition) SP-AngII-induced HO (using tin protoporphyrin; SnPP). We next examined whether additional chronic or late induction of SP-AngII-induced HO (using cobalt protoporphyrin; CoPP), prevents or ameliorates renal damage. We found that neither chronic nor late SnPP altered blood pressure. Chronic SnPP worsened SP-AngII-induced renal dysfunction, inflammation, injury and fibrosis, whereas late SnPP worsened renal dysfunction but not inflammation. Chronic CoPP prevented HTN, renal dysfunction, inflammation and fibrosis, but surprisingly, not the NGAL levels (renal injury marker). Late CoPP did not significantly alter SP-AngII-induced HTN, renal inflammation or injury, but improved renal function. Thus, we conclude (a) endogenous HO may be an essential determining factor in SP-AngII induced renal inflammation, injury and fibrosis, (b) part of HO's renoprotection may be independent of blood pressure changes; and (c) further induction of HO-1 protects against renal injury, suggesting a possible therapeutic target.

Highlights

  • Angiotensin II (AngII) is one of the major factors playing a role in the development of chronic kidney disease

  • heme oxygenase-1 (HO-1) is an important cytoprotectant which is induced in the kidney by oxidative stress, injury and certain hormones including AngII, and its role in modulating renal injury has been increasingly studied

  • We examined the effect of acutely inhibiting heme oxygenase (HO) on renal hemodynamics in rats that were treated with very low doses of SP-AngII (50 ng/kg/min IV) [11]

Read more

Summary

Introduction

Angiotensin II (AngII) is one of the major factors playing a role in the development of chronic kidney disease. Previous studies have demonstrated the importance of HO in dampening the hypertensive and renal vasoconstrictor effects of AngII [5,6,7] These studies employed pressor doses of AngII. A model that is more analogous to clinical situations is one in which AngII levels are elevated, but within a pathophysiologic range This is achieved by chronically infusing subpressor doses of AngII (SP-AngII). This model is characterized by the development of salt-sensitive hypertension (HTN), increased expression of proinflammatory factors, oxidative stress, and progressive renal injury [4, 5, 8,9,10].

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call